Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent Rare CNS Cancers
NCT03173950Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2017
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in central nervous system tumor, sponsored by National Cancer Institute. Primary endpoints: Disease Control Rate at 64 weeks, Disease Control Rate with 95% Confidence Interval at 64 weeks and 2 more. Started Jul 2017; status: terminated.
02
Drugs
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT03173950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173950.